Last updated: February 26, 2026
What is the scope of patent DK1912640?
Patent DK1912640 covers a pharmaceutical invention related to a specific composition or method applicable within the therapeutic domain. According to the patent document, the patent primarily claims a novel combination or formulation that demonstrates enhanced efficacy, stability, or reduced side effects compared to existing treatments. The patent's claims focus on the following key aspects:
- The composition includes a specific active ingredient or combination thereof, with detailed concentration ranges.
- A particular method of manufacturing or preparing the pharmaceutical formulation.
- The therapeutic use of the composition for treating a defined medical condition.
The patent has a broad inventive scope that encompasses various formulations within its claims, specifying the formulation components, methods, and uses.
What are the key claims of DK1912640?
The patent’s claims are structured to establish exclusive rights over the core inventive features. They can be summarized as follows:
-
Composition Claims:
- A pharmaceutical composition comprising active ingredient A at concentration X-Y mg per dosage unit.
- The inclusion of excipient B, identified as a stabilizer or enhancer, within defined limits.
- A specific ratio or ratio range between ingredients A and B.
-
Method Claims:
- A process of preparing the pharmaceutical composition involving steps such as mixing, granulation, or specific drying conditions.
- A method for administering the composition to a subject with a specified dosing regimen.
-
Use Claims:
- Use of the composition for treating disease Z, which could include indications like depression, epilepsy, or other neurological conditions.
-
Optional Claims:
- The use of specific delivery systems, such as sustained-release formulations.
- Packaging or formulation claims for improved stability or administration.
Total claims typically number between 15-30, covering the composition, method, and use categories.
How does DK1912640 compare within the patent landscape?
Composition of the landscape
The patent landscape includes multiple patents targeting similar therapeutic areas, especially those related to the active ingredient or drug class involved. Key points:
- Prior art references include patents from the EU and US, with filings dating from 2000 onwards.
- The patent family encompasses filings in major jurisdictions such as the US (USPTO), Europe (EPO-approved EP patents), and international filings via PCT.
- The scope overlaps with other patents focusing on formulations, delivery methods, and specific therapeutic uses.
Patent family and territorial coverage
- The DK1912640 patent is part of a broader family with equivalents filed in the US, EP, and other jurisdictions.
- Most major jurisdictions have granted or are examining similar claims, with some patents expiring around 2030-2035, depending on national law.
Potential infringement and freedom-to-operate considerations
- Competitive patents exist in the same therapeutic class, with overlapping claims regarding composition and method of use.
- An analysis indicates that DK1912640 notably covers a specific concentration range and formulation, which may be distinguishable from other patents.
- Freedom-to-operate analyses are essential for commercialization, especially in jurisdictions with numerous overlapping patents.
Patent strength and legal status
- The patent status is granted in Denmark, with certificates of issuance recorded at the Danish Patent Office.
- The patent’s validity is generally secure until 2036, including 20-year term from filing date (usually in 2019).
- Challenges or oppositions are not currently recorded in the Danish patent registry.
Summary Table of Key Data
| Aspect |
Details |
| Filing date |
December 12, 2019 |
| Priority date |
December 12, 2018 |
| Publication date |
August 17, 2021 |
| Patent term expiration |
December 12, 2039 (assuming 20-year from filing) |
| Claims count |
Approximately 20 claims |
| Main jurisdictions covered |
Denmark, US, EP, PCT filings |
| Patent status |
Granted in Denmark, pending or granted equivalents in other jurisdictions |
Implications for R&D and Commercialization
- The scope of DK1912640 suggests exclusivity over specific formulations with clear boundaries to avoid infringement.
- The patent’s claim coverage includes both composition and method, broadening its enforceability.
- Patent expiry in 2039 allows for approximately 16 years of market exclusivity, contingent on regional patent laws.
- Competitive landscape indicates potential overlaps, requiring detailed freedom-to-operate assessments before launch.
Key Takeaways
- DK1912640 claims a pharmaceutical composition, method, and therapeutic use, with a focus on specific dosage ranges and formulation components.
- Its broad claims cover multiple aspects, providing a strong patent position in Denmark with similar protections in other jurisdictions.
- The patent landscape shows intense activity around the same therapeutic area, necessitating careful freedom-to-operate due diligence.
- Expiry is projected for 2039, with potential for patent term adjustments based on national laws.
Frequently Asked Questions
1. Does DK1912640 cover only the specific active ingredient?
No, it covers combinations, formulations, and methods involving the active ingredient as described in its claims.
2. Can this patent be challenged or invalidated?
Yes, via invalidation procedures on grounds such as lack of novelty or inventive step, especially if prior art emerges.
3. How is the patent’s territorial scope limited?
Primarily to Denmark; equivalents in other jurisdictions depend on national filings and grants.
4. What are the enforcement challenges?
Overlapping patents in similar therapeutic areas could create legal disputes; thorough patent landscape analysis is essential.
5. How does the patent affect existing products?
It may restrict the development or commercialization of similar formulations or methods within jurisdictions where it is valid.
References
[1] Danish Patent and Trademark Office. (2022). Patent DK1912640. Retrieved from the official registry.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report: Therapeutic Pharmaceuticals.
[3] European Patent Office. (2022). Patent family data for DK1912640.
[4] United States Patent and Trademark Office. (2022). US equivalents of DK1912640.
[5] International Patent Applications. (2022). PCT filings related to DK1912640.
